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Background: Diethylhexyl phthalate (DEHP) is widely used as a plasticizer in polyvinyl chloride products. DEHP exposure,
which is widespread in the US, increases preterm birth risk; however, the mechanisms driving this relationship are
unclear. Because cyclooxygenase-2 (COX-2) dependent prostaglandin synthesis is implicated in preterm birth, we
evaluated effects of mono-2-ethylhexyl phthalate (MEHP), the active metabolite of DEHP, on prostaglandin E2 (PGE2)
synthesis and COX expression in human placental macrophages (PM). In addition, responses in PM were compared to
those in a human macrophage-like cell line, THP-1.
Methods: PM and THP-1 cells were treated for 2, 4, 8, or 24 h with MEHP concentrations ranging from 10 to 180
micromolar. PGE2 concentrations were assessed in culture medium using ELISA, and COX expression was determined
by western blot.
Results: Treatment of PM and THP-1 cells with 180 micromolar MEHP for 24 h significantly increased PGE2 release.
Co-treatment of PMs or THP-1 cells with 180 micromolar MEHP and the non-selective COX inhibitor indomethacin
reduced MEHP-stimulated PGE2 production. Similarly, co-treatment of PM and THP-1 cells with the COX-2 selective
inhibitor NS-398 resulted in a significant decrease in PGE2, suggesting that MEHP-stimulated PGE2 is dependent
specifically on increased COX-2 expression. Western blot analysis revealed a significant increase in COX-2 expression in
PM and THP-1 cells treated with 180 micromolar MEHP, and no changes in COX-1 expression, supporting the role of
COX-2 in MEHP-stimulated PGE2 synthesis.
Conclusions: The findings from this study are the first to demonstrate phthalate-stimulated PGE2 synthesis in PM
and warrant future studies into COX-2-dependent prostaglandin synthesis as a mechanism of toxicant-associated
preterm birth.
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Preterm birth is a serious health problem, affecting 21
million infants worldwide and half a million per year in
the US, and accounting for nearly one-third of all neo-
natal mortalities [1]. Intrauterine infection is the leading
cause of preterm birth, but only represents 40–70 % of
total preterm births [2, 3]. In fact, as many as half of pre-
term births are attributed to unknown causes [4]. A better* Correspondence: lauren.m.tetz@vanderbilt.edu
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controlling untimely labor is necessary to prevent preterm
birth and to improve maternal and fetal health.
A recent report from the Institute of Medicine high-
lights the importance of further research into factors
contributing to preterm birth, including environmental
factors such as pollutants [5]. Indeed, exposure during
pregnancy to some environmental toxicants, including
phthalate esters, increases risk for preterm birth [6–9].
Diethylhexyl phthalate (DEHP) is used widely as a
plasticizer in polyvinyl chloride (PVC) consumer pro-
ducts. Because DEHP is not covalently bound to PVC, itle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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food, or house dust. Following oral exposure, DEHP is
quickly metabolized by gut lipases to its active metabolite,
monoethylhexyl phthalate (MEHP), and excreted in the
urine. A recent study conducted by the US Centers for
Disease Control found measureable levels of MEHP in
80 % of urine samples analyzed, suggesting that exposure
to DEHP is widespread in the U.S. population [10].
Previous studies show that women who are more
highly exposed to DEHP during pregnancy have an
increased risk for preterm birth and other adverse
pregnancy outcomes including low birth weight and
pregnancy loss [7, 11–14]. Measureable levels of DEHP
metabolites, including MEHP, can be found in maternal
urine and serum, placental tissue, fetal cord serum, and
amniotic fluid, indicating that DEHP metabolites transfer
from maternal blood to the fetal compartment [14–17].
Despite the mounting epidemiological evidence demon-
strating an association between maternal DEHP exposure
and increased risk for preterm birth, the mechanisms
underlying these relationships are unclear.
Recent data collected by our laboratory suggest that
MEHP stimulates expression in human trophoblast cells
of PTGS2, the gene for COX-2 [18], an enzyme that is
critical for synthesis of uterotonic prostaglandins, pros-
taglandin E2 (PGE2) and prostaglandin F2α (PGF2α).
COX-2 dependent prostaglandin synthesis is a critical
event for the initiation of human parturition, regulating
myometrial contractions and tissue remodeling in the
gravid uterus [19]. Inhibition of prostaglandin synthesis
following administration of COX-2 inhibitors delays par-
turition and prevents early labor in rodents, and in vivo
exposure to bioactive prostaglandins induces myometrial
contractions, cervical ripening and early labor, sugges-
ting that untimely prostaglandin synthesis may drive pre-
term labor processes [19–22]. In humans, increases in
amniotic fluid PGE2 and PGF2α correspond with preterm
labor and precede spontaneous labor at term [23, 24].
Macrophages within the uteroplacental environment
are an important source of bioactive mediators including
prostaglandins and cytokines. Placental and decidual
macrophages express COX-2 and produce PGE2 in re-
sponse to LPS or the pro-inflammatory cytokine IL-1β
[25–29]. No studies to date have examined the effects of
environmental toxicants, such as MEHP, on inducible
COX-2 expression or prostaglandin secretion in macro-
phages from the utero-placental unit. However, several
published studies suggest that MEHP influences immune
function [30–32]. Therefore, in the current study, we
test the hypothesis that MEHP increases prostaglandin
secretion through induction of COX-2 expression in
human primary placental macrophages (PMs) and in the
human macrophage-like cell line, THP-1, to model pri-
mary placental and decidual macrophage behavior.Methods
This study was reviewed and approved by the Institutional
Review Boards (IRBs) at the University of Michigan
(#00035795, approval date 09/25/13) and Vanderbilt Uni-
versity (#131607, approval date 05/13/14). In compliance
with the IRBs, the placental tissues collected for this study
would otherwise have been discarded and the investigators
did not collect any personal identifiable information or
have direct interaction with subjects.
Reagents
We purchased dimethyl sulfoxide (DMSO), indome-
thacin, and phorbol-12-myristate-13-acetate (PMA) from
Sigma-Aldrich (St. Louis, MO, USA); charcoal-stripped
fetal bovine serum (FBS) from HyClone Laboratories
(Waltham, MA); RPMI 1640, Dulbecco’s Modified Eagle
Medium (DMEM), penicillin/streptomycin solution, and
phosphate buffered saline (PBS) from Life Technologies-
Invitrogen (Carlsbad, CA); MEHP from Accustandard
(New Haven, CT); LPS derived from Salmonella typhi-
murium from List Biological Laboratory (Campbell, CA);
COX-1 and COX-2 monoclonal antibodies, and NS-398,
from Cayman Chemical (Ann Arbor, MI); NONIDET
P-40 Substitute from Research Products International
Corp (Prospect, IL); and protease inhibitor tablets from
Roche (Indianapolis, IN).
Third trimester placental tissue acquisition
Placental tissue was collected from non-laboring women
undergoing normal, medically-indicated cesarean section
delivery between 37 and 39 weeks of gestation at the
University of Michigan Women’s Hospital Birth Center
or Vanderbilt University Medical Center. A total of 18
placentas were collected for placental macrophage isola-
tion. Tissue samples collected at Vanderbilt University
were provided by the Cooperative Human Tissue Network,
which is funded by the National Cancer Institute. Ex-
clusion criteria included the following: pre-eclampsia,
diabetes, multi-fetal pregnancy, collagen vascular disease,
cervical cerclage, immune-compromised conditions, bac-
terial vaginosis or clinical chorioamnionitis (as noted in the
chart or suspected by attending physician), prescription of
antibiotics in the past two weeks (with the exception of
routine, pre-operative antibiotics), cigarette smoking, third
trimester bleeding, major maternal medical conditions
(e.g., chronic renal disease, sarcoidosis, hepatitis, HIV), or
any condition requiring the tissues to undergo pathological
examination.
Placental macrophage isolation and culture
For placental macrophage isolations, a 30–60 g sample
of tissue was excised from the placenta and then trans-
ferred to the laboratory in sterile PBS. Isolation of mac-
rophages was performed as described previously [33].
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to a single cell suspension and loaded on a 25 %/50 %
Percoll gradient to remove cellular debris. Macrophages
were isolated from single cell suspensions using MACS
Miltenyi CD14 microbeads. Purity of freshly isolated
macrophages was ~85 % on average, as assessed by
percentage of viable, CD68+ cells, determined by flow cy-
tometry (see Additional file 1: Figure S1, for flow cyto-
metry data). After 24 h of adherence purification, purity of
macrophage cultures was 95 % or above as determined by
visual morphological inspection (see Additional file 1:
Figure S1 for placental macrophage image). Yields of pla-
cental macrophage cells per gram weight of tissue ranged
from 2e5–1e6 cells per gram weight of tissue. Cells were
seeded at a density of 200,000 cells per well in a polys-
tyrene, 24-well culture plate in RPMI with 1 % antibiotic/
antimycotic solution and 10 % charcoal dextran FBS
(RPMI +/+), and then incubated for 24 h in a humidified
atmosphere at 37 °C and 5 % CO2. Before treatment, cells
were visually inspected to verify proper morphology.
THP-1 cell culture
We used the THP-1 cell line as a model to compare to
primary placental macrophages because these cells are
easily obtained, are genetically clonal, and represent a
potential alternative model to primary cells for macro-
phage toxicity testing in cases where human placental
tissues are difficult to obtain. The human monocytic
leukemia cell line THP-1 was obtained from the Ameri-
can Type Culture Collection (ATCC, TIB-202; Manassas,
VA, USA) and cultured as described previously [34].
THP-1 cells were used in this study to model placental
and decidual macrophage behavior, as we have de-
monstrated previously [35]. THP-1 cells were seeded at
a density of 200,000 cells per well in a 24-well plate, cul-
tured overnight, and then differentiated into adherent,
macrophage-like cells by culturing with 100 nM PMA in
RPMI +/+ for 24 h at 37 °C and 5 % CO2. After differen-
tiation and before treatment, cells were washed once
with culture medium to remove residual PMA. PMA-
treated THP-1 cells were used for all THP-1 cell experi-
ments described in this study. For the indomethacin
studies, THP-1 cells were seeded at a density of 200,000
cells per well in a 96-well plate and cultured for 24 h fol-
lowing PMA treatment in RPMI +/+, before co-treating
with indomethacin and MEHP.
Placental macrophage and THP-1 cell treatment
Primary PMs and THP-1 cells were treated with
medium alone, 0.05 % DMSO (solvent control), or 10,
45, 90 or 180 μM MEHP in triplicate in RPMI 1640
medium (with L-glutamine without phenol red, supple-
mented with 100 U/mL penicillin and 100 μg/mL
streptomycin) for 2, 4, 8, or 24 h in a humidifiedatmosphere at 37 °C and 5 % CO2. For PM experiments,
experiments were repeated a minimum of 3 times, each
time using cells isolated from one woman’s placental tis-
sue, with treatments balanced across subjects. For THP-
1 experiments, experiments were repeated a minimum
of three times on different days. For indomethacin in-
hibitor experiments, cells were treated with solvent con-
trol or 180 μM MEHP and co-treated with either 1 or
10 μM indomethacin, a non-selective COX inhibitor, for
24 h. For COX-2 selective inhibition experiments, cells
were pretreated with 1 μM NS-398 for 30 min, and then
treated for 24 h with solvent control or 180 μM MEHP
with or without 1 μM NS-398. Effective inhibitor con-
centrations were identified based on preliminary con-
centration response curves in THP-1 cells, using
500 ng/mL LPS as an inducer of COX-2 (data not
shown). Concentrations of MEHP used for the current
study were sub-cytotoxic, as determined by a lactate de-
hydrogenase assay on treatment medium from PM and
THP-1 cells treated with 0, 45, 90, and 180 μM MEHP
for 24 h (data not shown).Prostaglandin quantification
We measured MEHP-stimulated prostaglandin secretion
in human primary PM cells and THP-1 cells in culture.
PGE2 and PGF2α concentrations in the culture medium
were quantified with enzyme immunoassay (EIA) follow-
ing the manufacturer’s recommended protocol (Cayman
Chemical, Ann Arbor, MI, USA).Western immunoblot for COX-1 and COX-2 protein
expression
THP-1 cells were seeded at a density of 5e6 cells per
dish in a 60-mm polystyrene culture dish and PMs were
seeded at a density of 10e6 cells per well in a 6-well
polystyrene culture plate. Following 24 h incubation,
cells were treated for 8 h with solvent control (0.05 %
DMSO), 180 μM MEHP, or 500 ng/mL LPS. Following
treatment, cells were lysed with ice-cold lysis buffer
(0.5 % NONIDET P-40 Substitute, 250 mM NaCl,
50 mM Tris–HCl, with 2X protease inhibitor tablets).
Protein was separated on a 10 % polyacrylamide gel and
then transferred to a PVDF membrane. All samples
were run alongside COX-1 and COX-2 positive control
lysates (human COX-2 control lysates were obtained
from Cayman chemical and COX-1 control lysates
were a gift from Dr. William L. Smith, University of
Michigan). Membranes were probed for COX-1 (anti-
human COX-1 mouse monoclonal antibody; 5 μg/mL),
COX-2 (anti-human COX-2 mouse monoclonal antibody;
0.5 μg/mL) and α-tubulin (anti-α-tubulin mouse monoclo-
nal antibody; 1:40,000) or GAPDH (anti-GAPDH rabbit
monoclonal antibody; 1:1000).
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Data for each cytokine were expressed as pg/ml and ana-
lyzed by ANOVA to test for treatment effect, followed
by Tukey post hoc pairwise comparison of means when
ANOVAs were statistically significant. For experiments
with replicates within an experimental day, mixed model
ANOVA was used with treatment as the fixed variable
and experiment day as the random variable. Data are
expressed as the mean ± SE of 3 different experimental
days for THP-1 cells or 3–4 women, depending on the
experiment, for placental macrophages.
Results
MEHP-stimulated prostaglandin synthesis in placental
macrophage cultures
Treatment of primary PMs with 180 μM MEHP but not
10, 45, or 90 μM MEHP for 24 h significantly increased
PGE2 release by 1.7-fold (Fig. 1a,b). Furthermore, treat-
ment with 90 or 180 μM MEHP significantly stimulated
PGF2α release from PM cells by approximately 1.5 and
1.8-fold, respectively (Fig. 1c). We observed no sta-
tistically significant effect of 180 μM MEHP on PGE2
concentrations after 2, 4, or 8 h compared to solvent
controls (Fig. 1a). However, there was a trend suggestive
of increased PGE2 at all time-points measured. The ef-
fects of 180 μM MEHP treatment on PGE2 synthesis
were reproducible in THP-1 cells used to model PM be-
havior (Fig. 1f,g).
Effects of COX inhibitors on MEHP-stimulated PGE2
release
Co-treatment with 1 μM indomethacin, a non-selective
COX inhibitor, significantly decreased MEHP-stimulated
PGE2 release in PMs and THP-1 cells by 77 % and 60 %,
respectively, compared to MEHP alone, confirming
COX-dependent PGE2 synthesis with MEHP stimulation
(Fig. 1d,f ). Furthermore, co-treatment of PMs or THP-1
cells with the COX-2 selective inhibitor NS-398 resulted
in significant decreases in PGE2 concentrations of 70 %
and 57 %, respectively, compared with MEHP alone,
suggesting that MEHP-stimulated PGE2 synthesis is
dependent on COX-2 activity, specifically.
MEHP effects on COX-1 and COX-2 protein expression in
placental macrophage and THP-1 cells
Western blot densitometric analysis revealed a significant
increase in COX-2 protein expression of approximately
2-fold in PMs treated with 180 μM MEHP (Fig. 2a,c) but
no significant changes in COX-1 expression (Fig. 2b,c),
supporting the role of COX-2 in MEHP-stimulated PGE2
synthesis. MEHP induction of COX-2 was also observed
in THP-1 cells (Fig. 3). Furthermore, 180 μM MEHP in-
duced COX-2 expression at levels comparable to thoseobserved with a potent pro-inflammatory stimulus, lipo-
polysaccharide (LPS; Figs. 2 and 3).
Discussion
Exposure during pregnancy to the common environ-
mental contaminant DEHP has been associated in epi-
demiologic studies with increased risk for preterm birth
[7, 11]. Because immune cells can be important sources
of uterotonic prostaglandins [36], the objective of the
current study was to determine the influence of MEHP,
a principle bioactive metabolite of DEHP, on prosta-
glandin synthesis in primary human PMs. Our results
demonstrate that MEHP-stimulated synthesis of utero-
tonic prostaglandins is dependent on the activity of
inducible COX-2 enzyme in both PMs and THP-1 cells.
Furthermore, MEHP induced COX-2 expression at levels
comparable to those observed with a potent pro-
inflammatory stimulus, lipopolysaccharide. We observed
significant effects with MEHP concentrations ranging
from 90 to 180 μM. These concentrations are within one
order of magnitude of average MEHP concentrations re-
ported by Lin et al. [37] in human umbilical cord serum
(35.7 μM) and human maternal serum (42.6 μM), but
are higher than concentrations reported by Latini et al.
[11] in their study of MEHP in umbilical cord serum
(average of 1.8 ± 2.2 μM, range of 0–10.6 μM). To our
knowledge, this study represents the first to examine ef-
fects of a reproductive toxicant on PMs. These findings
support MEHP-stimulated prostaglandin synthesis and
induction of COX-2 enzyme in PMs as a potential
mechanism for MEHP-associated preterm birth. More-
over, the similar responses we observed with the human
monocyte cell line THP-1 suggest that MEHP may have
a general immunomodulatory effect on prostaglandin
synthesis, which may have implications for other disease
outcomes as well.
The findings from the present study are concordant
with our previous findings demonstrating an increase in
PTGS2 mRNA expression in placental trophoblast cells
with 90 and 180 μM MEHP [18]. In addition, MEHP ex-
posure has previously been shown to induce expression
of COX-2 in immortalized murine liver cells, murine
spermatocytes, and rat alveolar macrophages at concen-
trations ranging from 200 to 1000 μM MEHP [38–40].
Notably, the present study includes the lowest effective
concentration yet reported for MEHP effects on COX-2
expression in an immune cell, to the best of our
knowledge.
Contrary to the findings from the present study,
Xu et al. observed decreased COX-2 expression in the
junctional zone of placenta from pregnant rats dosed
with 750 or 1500 mg/kg DEHP daily from gestational
day 0 to 19 [41]. The discrepancy between the current
study and the findings of Xu et al. may be explained by
Fig. 1 Effects of MEHP with and without indomethacin (INDO) or NS-398 on prostaglandin release from primary placental macrophage cells or
THP-1 cells. a Placental macrophages were treated for 2, 4, 8, or 24 h with DMSO (0.05 % v/v; solvent control) or 180 μM MEHP. b and c Placental
macrophages were treated for 24 h with 0 (0.05 % v/v DMSO; solvent control), 10, 45, 90, or 180 μM MEHP. d and e Placental macrophages were
treated for 24 h with DMSO (0.05 % v/v; solvent control) or 180 μM MEHP with or without 1 μM indomethacin or 1 μM NS-398. f and g THP-1 cells
were treated for 24 h with DMSO (0.05 % v/v; solvent control) or 180 μM MEHP with or without 10 μM indomethacin or 1 μM NS-398. EIAs for PGE2 or
PGF2α were performed on cell culture medium as described in the “Methods” section. N = 3-4 women per placental macrophage experiment, 1–3
replicates within each treatment group per experiment. N = 3 experiments for THP-1 cells. *p < 0.05, **p < 0.01, compared to solvent controls
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exposure, differences in responses to MEHP between
species, differences in cellular response due to chronic
in vivo, vs. acute in vitro exposure, or differences in MEHP
responses of whole placental tissue compared to isolatedplacental macrophage cells. Furthermore, although the
lowest effective dose of DEHP given in the Xu et al. study
resulted in a serum MEHP concentration of 234 μM, simi-
lar to the highest concentration used in the current study,
a significant amount of DEHP remained in the rat serum
Fig. 3 MEHP effects on COX-1 and COX-2 protein expression in THP-1 cells. Western blot and densitometry analysis of COX-2 (a and c) and COX-1
(b and d) in THP-1 cells treated for 8 h with DMSO (0.05 % v/v; solvent control), 180 μM MEHP or 500 ng/mL LPS. Western blot analysis was performed
on THP-1 cell lysates as described in the “Methods” section. All samples were run alongside COX-1 and COX-2 positive control lysates, seen on the far
right of the gel. N = 3–4 experiments. *p < 0.05, compared to solvent controls
Fig. 2 MEHP effects on COX-1 and COX-2 protein expression in placental macrophages. Western blot and densitometry analysis of COX-2 (a and c)
and COX-1 (b and d) in placental macrophages treated for 8 h with DMSO (0.05 % v/v; solvent control), 180 μM MEHP or 500 ng/mL LPS. Western blot
and densitometry analysis was performed on placental macrophage lysates as described in the “Methods” section. All samples were run alongside
COX-1 and COX-2 positive control lysates, seen on the far right of the gel. N = 3 women. *p < 0.05, compared to solvent controls
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could also be due to the additional presence of DEHP in
the serum of exposed rats.
The investigations presented here utilized both primary
placental macrophages and the human macrophage-like
THP-1 cell line. As noted in previous studies, THP-1 cells
respond similarly compared to primary placental and de-
cidual macrophages in their response to bacterial infection
[35]. However, no studies to date have compared THP-1
cells to primary placental macrophages in their ability to
respond to reproductive toxicants. Our data are the first
to demonstrate that THP-1 cells respond similarly to pri-
mary placental macrophages in their secretion of prosta-
glandins and induction of COX expression in response to
MEHP treatment. Thus, THP-1 cells may represent a
facile model of placental macrophages for investigating
the influence of environmental toxicants on macrophage
function.
The mechanism of MEHP-stimulated prostaglandin
synthesis in placental cells remains to be elucidated; how-
ever, recent evidence suggests that PPAR may be impor-
tant for MEHP modulation of inflammatory responses
[31, 32]. DEHP and MEHP are putative PPAR activators,
and several studies show that MEHP-mediated toxicity is
dependent on PPAR in a variety of tissue and cell types
[31, 42]. Furthermore, because PPAR is an important
regulator of inflammatory responses in macrophages, fu-
ture studies could examine PPAR activation as a potential
mechanism for MEHP-stimulated prostaglandin synthesis
in primary PMs [43].
In addition to effects on labor processes, MEHP-
stimulation of PGE2 synthesis may have implications for
innate immune function in the female reproductive tract.
Previous findings from our group suggest that exagger-
ated levels of PGE2 suppress immune responses against
intrauterine Group A Streptococcus infection [35]. Be-
cause intrauterine infection is an important causal factor
for preterm labor, future studies could examine the in-
fluence of MEHP-stimulated PGE2 synthesis on the pro-
gression of intrauterine infections.Conclusions
The findings from the current study demonstrate COX-
2-dependent stimulation of PGE2 by MEHP in primary
human PMs and THP-1 cells, suggesting that PMs may
be an important target of MEHP toxicity. Because COX-2
dependent prostaglandin synthesis is implicated in pre-
term labor processes, these findings may represent a
potential mechanism by which MEHP contributes to risk
for preterm birth. Furthermore, these findings support
future epidemiological research examining the influence
of DEHP exposure on prostaglandin synthesis in the uter-
oplacental unit.Additional file
Additional file 1: Figure S1. Placental Macrophage Culture Purity. In
this file, we have included the flow cytometry data from freshly isolated
macrophages showing CD68+ cell percentages and an image of the
placental macrophage cultures after 24 h of adherence purification.
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